Overview

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Status:
Recruiting
Trial end date:
2028-11-01
Target enrollment:
Participant gender:
Summary
To learn if giving tivozanib in combination with nivolumab can help to control advanced nccRCC.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
AVEO Pharmaceuticals, Inc.
Treatments:
Nivolumab
Tivozanib